Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-Matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 2, 2014, Pages 257-263

  Kanda, Junya ^a,b   Long, Gwynn D ^a   Gasparetto, Cristina ^a   Horwitz, Mitchell E ^a   Sullivan, Keith M ^a   Chute, John P ^a   Morris, Ashley ^a   Shafique, Michael ^a   Li, Zhiguo ^a   Chao, Nelson J ^a   Rizzieri, David A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Alemtuzumab; Haploidentical; Matched related; Matched unrelated; Reduced intensity

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CANCER RECURRENCE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR; ENGRAFTMENT; FEMALE; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOLOGIC MALIGNANCY; HLA MATCHING; HUMAN; HUMAN TISSUE; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; VIRUS INFECTION; YOUNG ADULT;

ALEMTUZUMAB; HAPLOIDENTICAL; MATCHED-RELATED; MATCHED-UNRELATED; REDUCED-INTENSITY;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; TISSUE DONORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS; YOUNG ADULT;

EID: 84893054481     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.11.010     Document Type: Article

References (19)

1. Horwitz M.E. Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemia. Curr Opin Oncol 2011, 23:197-202.
2. Bornhauser M., Kienast J., Trenschel R., et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial. Lancet Oncol 2012, 13:1035-1044.
3. Rizzieri DA, Long GD, Vredenburgh JJ, etal. Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. Blood (ASH annual Meeting Abstracts) 2001;98:2486-3488.
4. Chakraverty R., Orti G., Roughton M., et al. Impact of invivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood 2010, 116:3080-3088.
5. von dem Borne P.A., Starrenburg C.W., Halkes S.J., et al. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag'). Curr Opin Oncol 2009, 21(Suppl 1):S27-S29.
6. Kanda J., Lopez R.D., Rizzieri D.A. Alemtuzumab for the prevention and treatment of graft-versus-host disease. Int J Hematol 2011, 93:586-593.
7. Rizzieri D.A., Koh L.P., Long G.D., et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. JClin Oncol 2007, 25:690-697.
8. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013, 48:452-458.
9. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
10. Sullivan K.M., Agura E., Anasetti C., et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991, 28:250-259.
11. Gooley T.A., Leisenring W., Crowley J., Storer B.E. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
12. Kanda J., Horwitz M.E., Long G.D., et al. Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2012, 47:700-705.
13. Horwitz M.E., Morris A., Gasparetto C., et al. Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients. Biol Blood Marrow Transplant 2008, 14:591-594.
14. Ciurea S.O., de Lima M., Cano P., et al. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation 2009, 88:1019-1024.
15. Yoshihara S., Maruya E., Taniguchi K., et al. Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012, 47:508-515.
16. Ogawa H., Ikegame K., Yoshihara S., et al. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning. Biol Blood Marrow Transplant 2006, 12:1073-1084.
17. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
18. Brunstein C.G., Fuchs E.J., Carter S.L., et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011, 118:282-288.
19. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. JClin Oncol 2013, 31:1310-1316.